Calyxo (formerly Kalera Medical) is developing a disruptive solution for kidney stone removal that is faster, easier, and better for patients, clinicians and hospitals. Kalera Vacuum Aspiration Catheter (K-VACä) is the only solution that can remove multiple stone fragments in a single insertion, within seconds, and has the potential to deliver unsurpassed stone-free outcome.
The Problem: Presently, stone removal is the most unpredictable and difficult part of ureteroscopy because current tools, i.e. baskets, have serious limitations. The current stone removal devices are extremely time-consuming to use and often extend surgical time, while failing to deliver the desired efficacy. There is a clear unmet medical need for improved solutions and K-VAC is designed to deliver unparalleled stone-free outcome for the patients.
The Solution: Calyxo’s K-VAC has been specifically developed to deliver a highly efficient and complete stone removal in a simple, intuitive procedure. K-VAC has demonstrated highly predictable, outstanding efficacy within seconds, a clinical outcome that cannot be achieved with currently available devices.
Market Opportunity: Approximately 10% of the US population experience kidney stone disease during their lifetime, leading to more than $10 billion a year in treatment costs. The incidence of the kidney stone increases with age and is associated with a high rate of recurrence – a 50% recurrence within 5 years. Ureteroscopy is today’s gold standard procedure in kidney stone treatment and accounts for 60% to 70% of all kidney stone removal procedures. There are an estimated 1.5 million procedures worldwide and over 406,000 procedures annually in the U.S. alone.
Investment information is restricted to VIN members. Become a member to view investment opportunities.